NCT05841342

Prospective Study of Immune Function and PD-1 Antibody Therapy Efficacy Predictors on CAEBV and EBV-HLH Patients

A Prospective Study of Immune Function and PD-1 Antibody Therapy Efficacy Predictors for Chronic Active Epstein-Barr Virus Infection and Epstein-Barr Virus Associated Hemophagocytic Lymphohistiocytosis

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 128 (estimated)
• Sponsor: Beijing Friendship Hospital · Academic / Other
• Sex: All
• Age: 2 Years – 80 Years
• Healthy volunteers: Accepted

Summary

This prospective case-control study aims to evaluate the immune function and find PD-1 antibody efficacy predictors on Chronic Active Epstein-Barr Virus Infection and Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis by detecting lymphocyte subsets proportions in peripheral blood mononuclear cells and the positive proportion of PD-1, PD-L1 and other indicators in each lymphocyte subsets in healthy people and patients using flow cytometry before and after the initial PD-1 therapy.

Conditions

• Secondary Hemophagocytic Lymphohistiocytosis
• Chronic Active Epstein-Barr Virus Infection

Interventions

Type	Name	Description
OTHER	No intervention	No intervention

Timeline

• Start date: 2022-10-01
• Primary completion: 2024-04-30
• Completion: 2024-06-30
• First posted: 2023-05-03
• Last updated: 2023-05-03

Locations

1 site across 1 country: China